Are you ready to
break through the complexities
of type 2 diabetes?
Are you ready to
break through the complexities
of type 2 diabetes?
The bird now has been freed
According to the new 2022 ADA/EASD guidelines, combination injectable therapy of insulin/GLP-1 RA is recommended as ................ to achieve glycemic goals.
A. High efficacy approach
B. Very high efficacy approach
C. Intermediate efficacy approach
What can SOLIQUA provide for adults with type 2 diabetes insufficiently controlled on basal insulin? ( select all the right answers )
SOLIQUA manages ....................... meal fluctuations every day.
A. Pre
B. Post
C. Pre and post
Patients insufficiently controlled on Basal Insulin + OADs, SOLIQUA provides ................ HbA1c reduction vs premix insulin BIAsp 30 at week 26 (According to solimix trial).
A. Superior
B. Inferior
C. Comparable
SOLIQUA is a simple injection to be taken ...............................
A. Once or twice daily within the main meals
B. Twice daily with breakfast and dinner
C. Once daily within one hour prior to a meal
SOLIQUA can be titrated to address the patient’s needs
A. True
B. False
C. IT Depends
Combination injectable therapy is now recommended by new International guidelines in the main treatment algorithm for T2D management 1
Double efficacy on both
pre- and post-meal fluctuations
to help face the daily challenges of glycemic control
1
SOLIQUA
® lowered glycemic values at all time points for 7-point
self-monitored plasma glucose (SMPG)
1
When switching from basal insulin 1
In patients insufficiently controlled on Basal Insulin (+metformin +/- 1-2 OADs)
After 30 weeks, mean values at all time points were lower with SOLIQUA ® vs insulin glargine 100 U/ml with the exception of the prebreakfast value, which was similar (7 point SMPG) LS mean ± SE difference [mmol/L] vs Insulin glargine 100 U/ml -0.9 (95% CI -1.2, –0.6), p <0.0001.*1
Provides superior HbA1c reduction vs premix insulin 1
Superior HbA1c reduction from baseline premix insulin 1
HbA1c reduction from baseline to Week 261
More patients achieved HbA1c <7% premix insulin 1
Proportion of patients achieving HbA1c <7% at Week 26 (%)1
CI: Confidence interval, HbA1c: Hemoglobin A1c, LS: Least squares, OAD: Oral antidiabetic drug, OR: Odds ratio. *Adults who have been treated with any basal insulin combined with 1 or 2 OADs that could be metformin alone or metformin + an SGLT2 inhibitor. †For the HbA1c reduction the primary endpoint was non-inferiority, secondary endpoint assessed as well the superiority. Noninferiority p-value was calculated using a noninferiority margin of 0.3%.1 ‡Adjusted OR of iGlarLixi vs. BIAsp 30 with associated two-sided CI (at the specified significance level that is passed from family 1 of the primary objectives), calculated by logistic regression model adjusted for fixed categorical effects of randomization strata (basal insulin dose at screening <30 units and ≥30 units and SGLT2 inhibitor use [yes, no] at screening) and treatment group as well as fixed continuous covariates of baseline values for each of the primary end points (HbA1c and body weight).1 1. Rosenstock J, et al. Diabetes Care. 2021;44(10):2361-2370. 1
A simple, once daily injection that can fit easily into everyday life 1-4
Simple once daily
injection
1
Within 1 hour
before a meal
*1
Allows for gradual titration of GLP-1 RA (lixisenatide) along with basal insulin to address your patients' individual needs 1
The SOLIQUA® dose is titrated according to basal insulin requirement and the GLP-1 RA dose follows 1
Keep going to decrease the complexity and free the bird.
Let’s try more to decrease the complexity
Let's try more to help breaking through the complexity and free the bird.
